While daily administration of insulin and lifestyle modifications [5–7] have dramatically changed the disease prognosis in recent decades, the dosing adjustments of intensive insulin therapy and reductions in glycosylated hemoglobin (HbA1c) in order to minimize diabetes-related complications are still challenging in these patients with type 1 diabetes [8, 9]. The gene discussed is INS; the disease is type 1 diabetes mellitus.